In the pressing quest of novel treatments for chronic pain, α7 nAChR silent agonists show efficacy as anti-inflammatory modulators and represent a promising strategy. Recent findings reveal that a sulfonium ion can replace the quaternary ammonium nitrogen as an alternative pharmacophore for nAChR silent activation. This study reports the design, synthesis, and electrophysiological evaluation of a new series of sulfonium-based derivatives inspired by the archetypal silent agonist NS6740. Our findings identify NSS-9 as a novel sulfonium α7 silent agonist that effectively alleviates inflammatory pain in a mouse model, highlighting it as a lead compound for further optimization. These results provide insights into the potential of the sulfonium group as a chemotype interacting with the α7 binding site, making it a valuable scaffold for novel α7 silent agonists. Additionally, sulfonium compounds were tested on α9 nAChR, also involved in the cholinergic anti-inflammatory system, identifying one partial agonist and two antagonists.

Sulfonium Moieties as Ammonium Bioisosteres: Novel Ligands for the Alpha7 Nicotinic Acetylcholine Receptor / C. Papotto, C. Stokes, C. Matera, S.M. Herz, K. Chiang, R. Ferrisi, M. De Amici, M.I. Damaj, R.L. Papke, C. Dallanoce. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 68:3(2025 Feb 13), pp. 3157-3179. [10.1021/acs.jmedchem.4c02399]

Sulfonium Moieties as Ammonium Bioisosteres: Novel Ligands for the Alpha7 Nicotinic Acetylcholine Receptor

C. Papotto
Primo
;
C. Matera;R. Ferrisi;M. De Amici;C. Dallanoce
Ultimo
2025

Abstract

In the pressing quest of novel treatments for chronic pain, α7 nAChR silent agonists show efficacy as anti-inflammatory modulators and represent a promising strategy. Recent findings reveal that a sulfonium ion can replace the quaternary ammonium nitrogen as an alternative pharmacophore for nAChR silent activation. This study reports the design, synthesis, and electrophysiological evaluation of a new series of sulfonium-based derivatives inspired by the archetypal silent agonist NS6740. Our findings identify NSS-9 as a novel sulfonium α7 silent agonist that effectively alleviates inflammatory pain in a mouse model, highlighting it as a lead compound for further optimization. These results provide insights into the potential of the sulfonium group as a chemotype interacting with the α7 binding site, making it a valuable scaffold for novel α7 silent agonists. Additionally, sulfonium compounds were tested on α9 nAChR, also involved in the cholinergic anti-inflammatory system, identifying one partial agonist and two antagonists.
α7 Nicotinic Acetylcholine Receptor; α9 Nicotinic Acetylcholine Receptor; Sulfonium; Electrophysiological studies; Silent agonist; Synthesis; Inflammatory pain; CFA; Docking analysis;
Settore CHEM-07/A - Chimica farmaceutica
Settore BIOS-11/A - Farmacologia
13-feb-2025
20-gen-2025
Article (author)
File in questo prodotto:
File Dimensione Formato  
J.Med.Chem, 2025, 68, 3157-3179-compresso.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Accepted_Manuscript Dallanoce_J.Med.Chem. 2025.pdf

embargo fino al 20/01/2026

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.23 MB
Formato Adobe PDF
2.23 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1157209
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact